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Intravenous immunoglobulin (IVIg) is a polyclonal immunoglobulin G preparation with 
potent immunomodulatory properties. The mode of action of IVIg has been investigated 
in multiple disease states, with various mechanisms described to account for its ben-
efits. Recent data indicate that IVIg increases both the number and the suppressive 
capacity of regulatory T cells, a subpopulation of T cells that are essential for immune 
homeostasis. IVIg alters dendritic cell function, cytokine and chemokine networks, and T 
lymphocytes, leading to development of regulatory T cells. The ability of IVIg to influence 
Treg induction has been shown both in animal models and in human diseases. In this 
review, we discuss data on the potential mechanisms contributing to the interaction 
between IVIg and the regulatory T-cell compartment.
Keywords: intravenous immunoglobulin, regulatory T cell, dendritic cell, autoimmunity, immune modulation, 
cytokine
introduction
intravenous immunoglobulin
Intravenous immunoglobulin (IVIg) is prepared from polyclonal immunoglobulin G (IgG) purified 
from pooled plasma samples of several thousand healthy donors. IgG has been the standard treat-
ment for primary immunodeficiency diseases since Bruton’s identification of a patient with agam-
maglobulinemia in the early 1950s (1). However, Imbach et al. (2), in the early 1980s, demonstrated 
that administration of high doses of human polyclonal IgG in children with immune deficiency who 
concomitantly suffered from immune thrombocytopenic purpura (ITP) had a dramatic increase 
in platelet counts. Since then, there has been a progressive increase in the use of IVIg in patients 
Abbreviations: APC, antigen-presenting cell; CLRs, C-type lectin receptors; DC, dendritic cell; EAE, experimental autoim-
mune encephalitis; F(ab), fragment antibody-binding region; Fc, fragment crystallizable region; FcγR, Fc-gamma receptor; 
GFP, green fluorescent protein; IgG, immunoglobulin G; ITAM, immunoreceptor tyrosine-based activation motif; ITIM, 
immunoreceptor tyrosine-based inhibition motif; ITP, immune thrombocytic purpura; IVIg, intravenous immunoglobulin; 
KS, Kawasaki syndrome; MHC, major histocompatibility complex; NK, natural killer; saIVIg, sialylated fraction of IVIg; TCR, 
T-cell receptor; Treg, regulatory T cell.
September 2015 | Volume 6 | Article 4692
Kaufman et al. Treg induction by IVIg
Frontiers in Immunology | www.frontiersin.org
with a wide variety of autoimmune and inflammatory disorders. 
IVIg is used as a primary treatment for ITP, Kawasaki Syndrome 
(KS), Guillain–Barré syndrome, myasthenia gravis, chronic 
inflammatory demyelinating polyneuropathy, systemic lupus 
erythematosus, and other autoimmune and neurologic disorders 
(3). IVIg is commonly used in the prevention or treatment of 
neonatal sepsis. Rationally, those infants who are premature 
or suffer from very low birth weights should benefit from the 
immune supplementation provided by IVIg. However, large 
randomized clinical trials have failed to show consistent benefit 
in terms of prevention or outcomes from septic episodes (4–6). 
Novel preparations enriched in IgM may have some promise, but 
to date results are inconsistent (7, 8).
Intravenous immunoglobulin is now the most commonly 
prescribed plasma-based product worldwide (3, 9). This 
increased use raises questions regarding the long-term viability 
of this therapy. Considering the high cost and limited availability 
of this resource, it is imperative to investigate the underlying 
mechanisms of IVIg in order to tailor the anti-inflammatory 
response obtained by treatment, allowing for better therapies 
for inflammatory and autoimmune diseases. Furthermore, this 
can lead to the development of non-plasma-derived drugs with 
similar therapeutic benefits.
Many mechanisms explaining the immune-regulatory actions 
of IVIg have been postulated, including modulation of inhibitory 
Fc-gamma receptor (FcγR) expression, blockade of activating 
FcγR on antigen-presenting cells (APCs), interference with 
cytokine production, inhibition of cell activation, or induction of 
apoptosis in a variety of immune cells, including dendritic cells 
(DCs), macrophages, natural killer (NK) cells, and T and B lym-
phocytes (3, 9, 10). However, a key factor in immune modulation 
is the ability to counter inflammatory responses with regulatory 
cells. In this review, we will explore the links between IVIg and 
regulatory T-cell responses.
Regulatory T Cells
Regulatory T cells (Treg) were initially described in the 1990s 
as a specialized subpopulation of T cells that maintain immune 
system homeostasis and tolerance to self-antigens (11, 12). The 
transcription factor forkhead box P3 (FOXP3) is considered the 
marker of choice for this cell (13). FOXP3 is a master-switch 
transcription factor: its expression modifies T cells toward a 
regulatory phenotype, enabling many of the anti-inflammatory 
functions of Treg (14). The fundamental property that defines 
Treg is their ability to transfer immune suppression in vivo from 
one animal to another or in vitro from one cell culture to another 
(15). Based on their developmental or functional differences, Treg 
are categorized into two main populations: naturally occurring 
Treg that are generated in the thymus (tTreg) and peripherally 
induced Treg (pTreg) generated in peripheral lymphoid tissues 
from non-Treg precursor CD4+ cells. While Treg are CD4+ 
T-effector cells with characteristic FOXP3 expression, this is 
not sufficient to define a cell population as Treg: single-cell flow 
cytometric sorting experiments have shown the importance of 
elevated expression of the high-affinity IL-2 receptor, CD25, as a 
hallmark of Treg (16). Other markers, including HLA-DR, GARP, 
and low CD127 expression, along with CTLA-4 and Helios, are 
not entirely consistent or reliable and depend on the activation 
state of the cell (17). Recent work by Bin Dhuban et al. (18) has 
identified two cell-surface Treg markers: TIGIT, a novel CD28-
related protein, and FCRL3, an Fc-receptor-like glycoprotein, 
which allow for high-consistency detection of Treg in human 
peripheral blood mononuclear cells (PBMCs).
Pre-clinical studies have shown that freshly isolated or ex vivo-
expanded Treg can confer immunological tolerance in subjects 
with autoimmune and inflammatory disorders (19, 20). However, 
human Treg infusion therapy has been difficult to implement, and 
relatively few clinical trials have been initiated (21). Therefore, 
developing new therapeutic approaches with the capability 
to modulate the immune system through activation and/or 
expansion of Treg has been the subject of many recent studies. 
Several therapeutic immunosuppressive compounds, including 
rapamycin (22) and glucocorticoids (23), have been identified as 
promoting the expansion or suppressive activity of Treg.
Intravenous immunoglobulin has been proposed as a treat-
ment that can promote development or activation of Treg in 
autoimmune diseases (24). Herein, we provide an overview 
examining if IVIg indeed influences induction of Treg in the 
context of different inflammatory and autoimmune conditions 
and discuss mechanisms underlying Treg induction by IVIg.
evidence for the Action of ivig in the 
Promotion of Treg in Human Clinical Trials
An early clue suggesting regulatory effects of IVIg was the obser-
vation that T cells, purified from IVIg-treated individuals, had 
significant suppressive effects when cultured with proliferating 
T and B cells (25). Subsequent studies demonstrated that IVIg 
therapy was associated with enhanced mitogen-induced “sup-
pressor T-cell function” in rheumatoid arthritis (26), ITP (27), 
and pediatric acquired immune deficiency syndrome (28). More 
recently, Kessel et al. (29) demonstrated that in vitro culture of 
IVIg with peripheral T cells led to increases in intracellular TGF-
β, IL-10, and FOXP3 expression as well as improvement in their 
suppressive functions when cocultured with effector T cells.
T cells from patients treated with IVIg have been examined 
for increases in Treg. In Guillain–Barré syndrome, IVIg therapy 
increases the expression of FOXP3 and the production of inhibi-
tory cytokines in Treg (30). In systemic lupus erythematosus, 
IVIg-treated patients show significant increases in Treg numbers; 
moreover, IVIg appeared to convert naive FOXP3−CD25− into 
activated FOXP3+CD25+ Treg (31). Consistently, IVIg therapy 
of EGPA patients increased FOXP3+ Treg numbers and produc-
tion of IL-10 in CD4+ T cells (32). In mononeuritis multiplex, a 
peripheral neuropathy, steroid unresponsive patients treated with 
IVIg exhibit enhanced populations of Treg (33).
Mechanisms of Action of ivig in KS
Kawasaki syndrome is an acute systemic vascular inflammation, 
primarily affecting children. A single IVIg treatment is generally 
successful in reducing fever and associated disease manifestations 
(34). Extensive work has focused on characterizing the IVIg-
induced Treg response in KS. Burns et al. (35) investigated the 
link between TNF-α and IVIg therapy in KS, hypothesizing that 
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TNF-α inhibition may decrease cell activation. They determined 
that infliximab treatment does not interfere with Treg induction 
by IVIg, finding that the expansion of CD14+ CD86+ tolerogenic 
DC correlated with increased Treg after IVIg treatment. They 
postulate that the IVIg-induced Treg pool secretes IL-10 and 
responds to the Ig heavy-chain Fc region.
In a subsequent study from the same group, Franco et al. (36) 
investigated the specificity of IVIg-induced Treg in subacute KS 
patients. IVIg treatment induced a subset of Treg that expressed 
high levels of CTLA-4, and secreted IL-10, but not TGF-β. This 
Treg expansion appeared to be key to controlling vascular inflam-
mation in KS. Cloned Treg expanded ex vivo only responded to 
soluble IgG Fc and not to F(ab)′2 fragments, indicating that these 
Treg were Fc-specific and that the mechanism was likely T-cell 
receptor (TCR)-dependent. Coculture experiments revealed 
that the Fc region of IgG was presented in a major histocompat-
ibility complex (MHC)-restricted, TCR-mediated manner by 
EBV-transformed B cells. Further investigation of the Fc peptide 
specificities of the tTreg population revealed similar profiles in 
both IVIg-treated KS patients and in healthy controls, suggesting 
that Treg responses are functionally inadequate in KS and that 
this can be reversed by IVIg (37).
In KS patients, IVIg treatment enhances the expression of 
genes related to Treg activation, including FOXP3, CTLA4, 
GITR, and TGFB1. The expression levels of these genes were sig-
nificantly lower in KS patients prior to treatment than in healthy 
controls (38, 39). Ni et al. (40) examined the mechanisms of Treg 
dysfunction in KS, focusing on microRNAs (miR). While acute 
KS patients had lower Treg numbers and decreased Treg marker 
expression, IVIg treatment increased Treg numbers and FOXP3, 
CTLA4, and GITR gene expression. Treg from untreated KS have 
down-regulated miR-155 and miR-21 microRNAs; miR-155 
down-regulation leads to increased SOCS1 signaling, decreased 
STAT-5 signaling, and miR-31 microRNA overexpression. IVIg 
treatment reversed these effects, restoring the SOCS1/STAT5 
balance and decreasing miR-31 expression. FOXP3-dependent 
miR-155 inhibited SOCS1, and STAT3 suppressed miR-21, which 
down-regulated FOXP3. IVIg treatment of KS patients lowered 
elevated IL-6 and pSTAT3, restoring miR-21 levels, providing 
an explanation for the increase in Treg numbers following IVIg 
infusion.
Modulatory effects of ivig in Animal 
Models of inflammatory Disorders via Treg 
expansion and induction
Role of ivig in experimental Autoimmune 
encephalomyelitis
In experimental autoimmune encephalomyelitis (EAE), an 
antigen-driven murine model of multiple sclerosis, IVIg 
treatment reduced the disease severity scores, promoted the 
expansion of Treg and enhanced their suppressive capacity, 
both in  vivo and in  vitro (39). Importantly, administration of 
IVIg failed to confer protection in EAE mice that were depleted 
of Treg prior to treatment, suggesting a critical role of endog-
enous Treg in conferring protection by IVIg. In line with these 
findings, Okuda et al. (41) replicated the effects of IVIg in EAE 
and showed that sulfonated IVIg was effective in increasing the 
frequency of Treg.
A potential target for IVIg in EAE is NK cells. NK cells have a 
wide variety of immunomodulatory functions, interacting with 
B cells, DC, and Treg (42, 43). Chong et al. (44) hypothesized 
that in IVIg-treated subjects, NK cells suppress disease by 
regulating inflammatory T-cell responses. Using an EAE model, 
they demonstrated that IVIg treatment blocks EAE develop-
ment and reduces demyelination by diminishing IL-17 and 
IFN-γ. NK cell depletion by anti-asialo GM1 antibody resulted 
in the loss of IVIg-mediated protection, and adoptive transfer 
of IVIg-treated NK cells was as equally protective as IVIg 
treatment. IVIg-treated NK cells induced CD4+ Foxp3+ Treg in 
spleen and draining lymph nodes, which were suppressive to 
antigen-specific effector T cells in ex vivo proliferation assays. 
Upon further investigation using an in vitro coculture system, 
Treg induction was determined to depend on IL-2 and TGF-β1 
production by NK cells. Chong et al. posit that IVIg may pro-
mote redistribution of NK cells in peripheral tissues, depending 
on the inflammatory stimulus. Since NK cells modulate their 
chemokine receptor expression to facilitate migration to local 
and peripheral sites of inflammation (45), IVIg may increase 
NK cell homing to inflammatory microenvironments and sec-
ondary lymphoid organs, where they can induce Treg. NK cell 
costimulatory molecule expression may also drive Treg induc-
tion: IL-2 and plate-bound anti-CD16 treatment up-regulate 
CD86 and OX-40 ligand on NK cells in  vitro (46). CD86 has 
been implicated in Treg generation (47), and OX-40 ligand can 
deliver a survival signal to Treg (48).
Treg induction in Allergen-Driven and 
Autoimmune Models
We have recently demonstrated, using an ovalbumin-driven 
murine model of allergic airway disease, that therapeutic 
administration of IVIg attenuated airway hyper-reactivity 
(AHR) and alleviated airway inflammation. This was accom-
panied by induction of highly suppressive, antigen-specific 
Treg derived from pre-existing T-effector cells. Treg induc-
tion was dependent on the interaction of IVIg with CD11c+ 
DC (49). Similarly, in a murine model of ITP, IVIg increased 
thymic and splenic Treg, accompanied by restoration of plate-
let counts (50).
Different dosing regimens have been used for IVIg to increase 
Treg (51). Our laboratory, as well as most other groups, uses high-
dose IVIg (2 g/kg), which is analogous to the immunomodula-
tory dose used in clinical practice (49). Other studies have used 
typical antibody-replacement doses of 400–800  mg/kg (52). 
Ramakrishna et  al. (53) reported an anti-inflammatory effect 
using extremely low-dose IVIg (187.5 mg/kg) in a HSV-mediated 
encephalitis murine model, which was felt to be dependent on 
enhancement of Treg. This dose range is rarely used clinically, 
making this work difficult to apply to standard practice. In 
addition, work from our laboratory and others (38, 54) suggests 
that a minor fraction of IVIg is required for some, but not all 
immunomodulatory effects. This will be discussed in more detail 
below.
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Mechanisms of Action of ivig in induction 
of Treg
The mechanisms by which IVIg induces Treg may involve direct 
interaction of IgG with T cells, or modulation of other cellular 
or molecular targets, particularly APCs such as DC and mac-
rophages. IVIg can also interact with other cells, such as B cells 
or NK cells. In addition, IVIg can modulate the production of 
proinflammatory cytokines, which may play a role in maintaining 
T-cell tolerance.
The effect of ivig on DC Activation
Induction of protective T-cell responses requires naive T cells to 
receive signals via the TCR, costimulatory molecules, and cytokine 
receptors. These signals, via cell–cell contact and through soluble 
mediators, are provided by professional APCs, such as DC. While 
DC represent the most efficient APC in capturing, processing, 
and presenting antigens to T cells (55), DC also play an active 
role in maintaining immune tolerance, as constitutive DC abla-
tion results in spontaneous fatal autoimmunity (56). Tolerogenic 
DCs are characterized by decreased expression of costimulatory 
molecules (CD40, CD80, and CD86), decreased antigen pres-
entation (due to reduced MHC class II expression), enhanced 
expression of coinhibitory molecules (e.g., PD-L1, CTLA-4, and 
OX-40), and enhanced inhibitory cytokine production (57, 58). 
This DC subset is essential for maintaining tolerance via extra-
thymic induction of pTreg and maintenance of pre-existing tTreg 
(59–62).
Induction of tolerance is critically dependent on the matura-
tion state of DC. An immature DC phenotype is associated with 
induction, expansion, or enhancement of the suppressive capac-
ity of Treg (63). Direct cell-to-cell interaction of DC and T cells 
via TCR (64), induction of indolamine-2,3-dioxygenase (IDO) 
(65), as well as secretion of IL-10, TGF-β, and retinoic acid by DC 
(66) are all implicated in the peripheral induction or expansion 
of Treg by DC.
Although both myeloid and plasmacytoid DC may be involved 
in maintaining peripheral tolerance (67), polyclonal human IgG 
appears to target CD11c+ DC rather than CD11c− plasmacytoid 
DC (49, 68). We have demonstrated that CD11c+ DC from IVIg-
treated mice are necessary and sufficient for peripheral induction 
of Treg in lung and draining thoracic lymph nodes (49). IVIg 
decreases CD80 and CD86 both in vitro and in vivo; in addition, 
adoptively transferred IVIg-treated DC can increase Treg in lungs 
of antigen-exposed and challenged mice (49, 69).
Intravenous immunoglobulin-exposed CD11c+ DCs are less 
competent in driving lymphocyte proliferation, potentially due to 
decreased MHC-II and CD80/CD86 expression (68, 70–72). Work 
from the group of Bazin suggests that internalized IVIg interferes 
with antigen presentation by competing with antigen peptides 
for loading on MHC-II molecules in the intracellular MHC-II 
compartment (MIIC) (73, 74). Inhibition of T-cell responses by 
reducing antigen presentation may also interfere with the activa-
tion of autoreactive pathogenic T cells. In addition, IVIg alters 
the pattern of DC cytokine production, including up-regulation 
of inhibitory cytokines, such as IL-10, and down-regulation of 
proinflammatory cytokines, such as IL-12 and IFN-γ (53, 71, 75).
Proinflammatory cytokines counteract Treg differentiation 
or decrease Treg suppressive effects. For example, IL-6 secretion 
from DC is known to abrogate Treg anergy, reverse Treg sup-
pression, and skew Treg differentiation toward Th-17 (76, 77). 
In contrast, IVIg reduces the production of IL-6 and TNF-α by 
peripheral blood monocytes (78, 79); it can therefore maintain 
Treg homeostasis. It is conceivable that IVIg-generated Treg may 
attenuate DC maturation by anti-inflammatory cytokine produc-
tion, expanding the inhibitory effects of IVIg by further tolerizing 
DC in a negative feedback loop.
How IVIg targets DC is still incompletely elucidated, and dif-
ferent mechanisms have been postulated. The effect of polyclonal 
IgG on DC appears to involve activating FcγR, by triggering 
immunoreceptor tyrosine-based activation motifs (ITAM) 
(80). However, both Fc and F(ab′)2 fragments of IgG have been 
shown to suppress DC maturation and modulate DC cytokine 
production (71). F(ab′)2 fragments have been shown to inhibit 
LPS-induced phosphorylation of extracellular signal-regulated 
kinase (ERK1/2), an intracellular signaling molecule that medi-
ates the inflammatory response induced by Toll-like receptor 
(TLR) ligation in DC (81).
Although a full discussion of IVIg-Fcγ receptor biology is 
beyond the scope of this review, it is important to note that inhibi-
tory FcγRIIB were required for the anti-inflammatory effects of 
IVIg in murine models of ITP (72), nephrotoxic nephritis (82), 
and epidermolysis bullosa acquisita (EBA) (54). Similarly, we 
have found that FcγRIIB is required for IVIg-mediated abroga-
tion of allergic airways disease (Kaufman et al., in preparation). 
Up-regulation of FcγRIIB expression on DC, and on APC in 
general, likely plays a role in the suppression of DC activation, 
although no direct physical interaction between IVIg with this 
receptor has been reported (83).
De Groot et al. (84) proposed another DC-dependent mecha-
nism by which IVIg promotes Treg expansion. They described 
promiscuous IgG-derived T-cell epitope peptides (Tregitopes) 
containing epitopes from both Fc and Fab fragments of the IgG 
molecule, with the capability of activating Foxp3+ Treg. They 
postulated that these Tregitopes are presented in the context of 
MHC-II by APC to Treg and contribute to Treg activation and 
expansion (85, 86). This is consistent with the results of Franco 
et al. (36) discussed earlier where B cells presented Fc regions of 
IgG in a MHC-restricted and TCR-mediated manner.
The Anti-inflammatory effects of Sialylated igG 
and its Relationship to Treg Development
Human IgG therapy has two consistently used dosing regimens. 
Patients requiring immune supplementation for immune defi-
ciency typically receive between 400 and 800  mg/kg monthly. 
After many years of using lower doses, these were deemed ineffec-
tive in crossover studies. Individuals requiring immune modula-
tion frequently receive infusion of IVIg containing two to five 
times the immune supplementation dose. It has therefore been 
hypothesized that minor fractions of IVIg provide molecules that 
supply the anti-inflammatory components needed for immune 
modulation. This has been demonstrated regarding specific neu-
tralizing antibodies, anti-idiotypic antibodies, or anti-apoptosis 
antibodies.
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The Ravetch group developed the concept that the anti-
inflammatory properties of IVIg were isolated to an IgG subset 
characterized by terminal α-2,6-sialylation of the Fc glycan. 
Specifically, the Fc portion of the IgG molecule contained an 
N-linked glycan moiety covalently bound to a highly conserved 
glycosylation site at Asn297 (87, 88). In various clinical scenarios, 
lower serum levels of sialylated IgG were found in individuals 
with systemic lupus erythematosus or juvenile-onset rheumatoid 
arthritis when compared with healthy controls (89–91). This 
sialylated fraction of IVIg (saIVIg) makes up roughly 1–2% of the 
total IgG in pooled therapeutic preparations. In proof-of-concept 
studies, saIVIg was therapeutically effective in animal models of 
rheumatoid arthritis (92), ITP (93), and allergic airways disease 
(94) at doses 10 times lower than unfractionated IVIg.
The mechanism of action of saIVIg is still under investigation. 
Kaneko et al. (87) proposed that saIVIg interacts with DC-SIGN 
(DC-specific intercellular adhesion molecule-3 grabbing 
non-integrin) on human DC or the murine ortholog SIGN-R1 
(specific intracellular adhesion molecule-3 grabbing non-
integrin homolog-related 1) on murine splenic macrophages. 
This triggers increased expression of the inhibitory Fc receptor 
FcγRIIB (88). This may contribute to the induction and expan-
sion of Treg; FcγRIIB-deficient mice are incapable of generating 
Treg in a model of mucosal antigen tolerance (95). Guilliams et al. 
reviewed the role of FcγRIIB in IVIg therapy and suggested that 
IVIg increases FcγRIIB expression in inflamed tissues during the 
effector phase of the immune response (96).
Using experimental models of multiple sclerosis (EAE) and 
serum-induced arthritis, Fiebiger et  al. (97) recently reported 
that saIVIg Fc confers protective effects in T-cell-mediated and 
antibody-mediated diseases. They developed a mutated IgG 
Fc construct (F241A), which had a similar structure to saIVIg 
Fc, but displayed DC-SIGN binding independent of sialyla-
tion. Both saIVIg Fc and F241A IgG Fc alleviated arthritis and 
EAE by inducing Treg expansion and activation, up-regulating 
FcγRIIB on effector macrophages, and suppressing Th17 and Th1 
responses. The anti-inflammatory responses required expression 
of DC-SIGN as well as secretion of IL-33 by macrophages.
Washburn et al. described a novel hypersialylated IgG deriva-
tive, tetra-Fc-sialylated IVIg (s4-IVIg), which was maximally 
sialylated but lacked advanced glycation end products (AGEs) 
that are hazardous to human health. s4-IVIg was efficacious in 
animal models of arthritis, ITP, and EBA (91). These results sub-
stantiate data obtained by Schwab et al. (54) who demonstrated 
requirements for IgG sialylation and FcγRIIB expression in their 
disease models.
As IVIg is a heterogeneous compound, it is not surprising that 
non-sialylated IgG is also biologically active. Othy et al. demon-
strated the effects of IVIg on Th17 and Treg cells independent 
of Fc sialylation (98). Similarly, there are studies using different 
murine models of ITP (99, 100) and rheumatoid arthritis (101), 
which did not require sialylated IgG. Differences in strains or 
induction of pathological conditions in various murine models 
are reasons for the discrepancies in the dependence on sialyla-
tion. To obtain more definitive results, it will be critical to evaluate 
the role of minor IgG fractions in subjects with inflammatory and 
autoimmune diseases.
ivig Binds C-Type Lectin Receptors on DCs
DC-specific intercellular adhesion molecule-3 grabbing non-
integrin and SIGN-R1 are C-type lectin receptors, which bind 
mannosylated and fucosylated structures, such as HIV envelope 
protein gp120 (102). While ligation of DC-SIGN by mannose-
expressing pathogens stimulates proinflammatory cytokine 
secretion by DC, fucose-expressing pathogens or synthetic 
fucose-containing ligands inhibit LPS-induced production of 
IL-6 and IL-12 and stimulate the secretion of anti-inflammatory 
IL-10 by DC (103). Hence, ligation of these innate receptors by 
saIVIg may regulate cytokine production by DC and therefore 
contribute to Treg homeostasis. Smits et  al. (104) showed that 
binding of Lactobacillus reuteri and Lactobacillus casei bacteria 
to DC-SIGN on monocyte-derived DC drove the development 
of Treg. These Treg produced increased levels of IL-10 and were 
capable of inhibiting the proliferation of bystander T cells in an 
IL-10-dependent fashion.
Work from the group of Ravetch and other investigators sug-
gests that the conformational changes in IgG molecules induced 
by sialylation lead to a reduction in binding affinity of IgG to FcγR 
by masking the FcγR binding site (105). Furthermore, sialylation 
exposes a binding site on IgG for carbohydrate-binding C-type 
lectin receptors such as DC-SIGN or SIGN-R1 (89, 97, 106). In 
contrast, the group of Crispin were unable to reproduce these 
findings, claiming that sialylation of IgG does not result in con-
formational changes to the IgG molecule or increases in binding 
affinity of IgG to DC-SIGN (107, 108). They suggest that cross-
linking of sialic-acid-binding Siglecs (sialic acid binding Ig-like 
lectins), such as CD22, and direct binding of Fc receptors induce 
inhibitory signaling through immunoreceptor tyrosine-based 
inhibition motif (ITIM) pathways. We have recently described 
that IVIg efficiently modifies DCs to induce regulatory T cells 
in the absence of activating FcγR (94). It is worth noting that the 
sialylation of IgG is not restricted to the Fc fragment, and a high 
proportion of sialic acid residues on the F(ab′)2 fragments of IgG 
has been identified recently by Kasemann et al. (109).
In addition to DC-SIGN, other C-type lectin receptors may 
interact with IVIg and contribute to induction and/or expansion of 
Treg. We have recently reported (94) that saIVIg specifically inter-
acts with the C-type lectin dendritic cell immunoreceptor (DCIR) 
on CD11c+ DC. This appears to lead to internalization of IgG into 
DC and is associated with inhibitory signaling in ligated DC that 
consequently results in the peripheral induction of Foxp3+ Treg. 
The contribution of DCIR+ DC in the induction and expansion 
of Treg has been demonstrated in previous studies, although not 
in the context of IVIg therapy. Yamazaki et al. (110) showed that 
two subsets of CD8+CD205+ and CD8−DCIR+ DC differentiate 
peripheral Foxp3+ Treg, in part through the endogenous produc-
tion of TGF-β. These data indicate that multiple C-lectin receptors 
are implicated in the generation of tolerogenic DC by IVIg.
interaction of ivig with Treg
Direct interaction of polyclonal IgG with Treg may represent 
another mechanism by which IVIg can induce tolerance. Kessel 
et al. (29) demonstrated that IVIg increases expression of intra-
cellular FOXP3, TGF-β, and IL-10 when added to culture with 
human CD4+ T cells. IgG was shown to bind to both human 
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and mouse Treg (39, 111), which increased FOXP3 expression, 
accompanied by augmented ex vivo suppressive function. IVIg 
stimulated phosphorylation of ZAP-70 in Treg (111), which is 
known to enhance suppressive activity (112).
Additionally, interaction of IgG with effector T cells can 
affect the balance of cytokine production, mainly by down-
regulating proinflammatory cytokines, such as IL-2, IFN-γ, and 
TNF-α, and increasing inhibitory cytokines (113, 114). Early 
work (115) on cytokine networks elucidated that IVIg abro-
gated production of both Th1- and Th2-type proinflammatory 
cytokines from PBMC in culture. Maddur et  al. (116) dem-
onstrated the reciprocal enhancement of Treg differentiation 
compared to inhibition of Th17 differentiation in culture, in 
association with decreases in Th17 effector cytokines (IL-17A, 
IL-17F, IL-21, and CCL20). In clinical trials, two groups have 
investigated the effect of IVIg therapy on the profile of intracel-
lular cytokine expression in T cells. In ITP patients who were 
responsive to IVIg therapy, there was increased production of 
IL-10 and TGF-β by CD4+ T cells as well as decreased Th-1 
cytokine production (117, 118).
Experiments from our laboratory could not confirm direct 
action of IVIg on T cells on the induction of Treg. We examined 
naive CD4+ Foxp3− T cells from Foxp3-GFP reporter mice in the 
absence of APC. Pre-treatment of these cells with IVIg, followed 
by coculture with DC and a source of antigen, did not result in the 
induction of Foxp3 expression, whereas IVIg pretreatment of DC 
prior to coculture induced Treg ex vivo. Further, we found that 
(49), in allergic airways disease, Treg induction required CD11c+ 
DC both in vitro and in vivo, suggesting that the DC compartment 
is the main target of IVIg in our system. We therefore hypothesize 
that IVIg first tolerizes DC, which in turn induce Treg.
Modification of chemokine or chemokine receptors on cir-
culating leukocytes is another potential mode of action of IVIg, 
which would lead to recruitment of cells to specific tissue sites. 
Evidence suggests that Treg compartmentalization and trafficking 
are tissue- or organ-specific and that distinct chemokine receptor 
and integrin expression may contribute to selective trafficking of 
Treg to inflammatory microenvironments (119). For instance, 
expression of chemokine receptors CCR4 and CCR8 are required 
on Treg for tissue homing (120). Treg may switch their homing 
receptor expression profiles depending on the direction of their 
trafficking. A majority of Treg found in secondary lymphoid 
tissues express CD62L and CCR7 (121). Moreover, while both 
effector and regulatory T cells might express similar patterns of 
chemokine receptors, both subsets may compete for interaction 
with APC or access to the site of inflammation.
We have demonstrated in a mouse model of ovalbumin-
driven allergic airway disease that IVIg specifically increases the 
expression of CCR4 on the induced Treg population, suggesting 
their enhanced ability to recruit to the site of inflammation. 
Additionally, we found that expression of CD62L, which acts as a 
homing receptor for lymphocytes entering secondary lymphoid 
tissues, is decreased in Treg isolated from inflamed lung tissues 
(49). In a murine model of ITP, Treg compartmentalization was 
also modified by IVIg therapy (50), stressing the potential for 
action of IVIg on chemokine receptor expression. It is unclear if 
this action is direct or indirect, via signals from APC.
Conclusion
Intravenous immunoglobulin is an extremely complex prepara-
tion that contains a multitude of biologically active moieties: it 
likely achieves immunomodulation through a number of syner-
gistic mechanisms, which provide positive therapeutic effects. The 
immune-regulatory effects of IVIg appear to be pleiotropic and 
involve different stages of the inflammatory cascade, with a com-
plex interplay of IgG molecules with different cells and mediators.
In this review, we describe potential mechanisms behind the 
actions of IVIg in the generation and differentiation of Treg. Recent 
findings reinforce the efficacy of IVIg in the enhancement of Treg 
in various autoimmune disorders. The action of IVIg in the modu-
lation of Treg, and the consequent maintenance of immune toler-
ance, provides a rationale for therapeutic approaches specifically 
targeting this axis of the immune system. This also renews interest 
in developing alternative treatments, such as Tregitopes or mono-
clonal antibodies, for refractory inflammatory and autoimmune 
diseases, which are often associated with deficiencies in Treg and 
are difficult to manage with conventional therapeutic approaches.
The effects of IVIg on the potentiation of Treg appear to 
involve the interaction of IgG with APC and potentially T cells 
and are dependent on the modulation of cytokine networks 
within different immune cell types. Based on our own studies 
and the conclusions of this review, we suggest a set of potential 
cellular mechanisms, which are summarized schematically in 
Figure 1. Initially, saIVIg binds C-type lectin receptors on DCs 
(Figure  1A), which induces inhibitory FcγRIIB expression on 
DC or on effector macrophages (Figure 1B), thus potentiating 
the activation threshold of the adaptive arm of the immune 
system. The associated inhibitory receptor signaling renders the 
DC tolerogenic, reducing DC costimulatory molecule expression 
(Figure 1C) and proinflammatory cytokine secretion (Figure 1D). 
Anti-inflammatory cytokine and mediator production by both 
DC and Treg (Figure  1E) and presentation of IgG regulatory 
epitopes (Figure 1F) to Treg by DC decrease proinflammatory 
cytokine production in naive effector T cells (Figure  1G) and 
generate Treg from non-Treg precursors (Figure  1H). These 
Treg inhibit effector Th1, Th2, and Th17 cell proliferation and 
activity (Figure 1I) in the inflammatory microenvironment and 
secrete anti-inflammatory cytokines (Figure  1E) that tolerize 
DC. In addition, IVIg-mediated modulation of chemokine or 
chemokine receptor expression in T-cell subsets might contribute 
to the homeostasis or regulation of trafficking of Treg, although 
proper functional characterization is needed. NK cells play a role 
in processing of innate antigens and have multiple known ITIM-
linked receptors: IVIg may target NK cells to directly induce Treg 
by cytokine production or cell–cell contact (discussed earlier). 
IVIg-treated NK cells may also induce antibody-dependent cel-
lular cytotoxicity of mature DC, which reduces antigen presenta-
tion and inhibits proinflammatory effector T-cell function (122).
Interaction of sialylated IgG with C-type lectin receptors 
triggers an inhibitory response in ligated cells that might 
consequently provide the required signals for maintaining 
immune tolerance. In this review, we bring evidence that shows 
the association of this interaction with the promotion of Treg. 
However, more investigation is still required to elucidate the 
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beneficial effects of IVIg in modulation of Treg, particularly in 
clinical trials. Further avenues of research include identifying 
specific cellular markers or phenotypic patterns associated with 
DC tolerogenicity as well as precise characterization of the IVIg-
generated Treg population.
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FiGURe 1 | ivig tolerizes DC, which interacts with T cells to induce Treg. Sialylated IVIg ligates C-type lectin receptors on DC (A), which induces FcγRIIB 
expression (B) and reduces costimulatory molecule expression (C) and proinflammatory cytokine secretion (D). Anti-inflammatory cytokine and mediator production 
(e) and presentation of IgG regulatory epitopes (F) decrease proinflammatory cytokine production in naive effector T cells (G) and generate Treg from non-Treg 
precursors (H). These Treg inhibit effector Th1, Th2, and Th17 cell proliferation and activity (i) in the inflammatory microenvironment and secrete anti-inflammatory 
cytokines (e) that tolerize DC. CLRs, C-type lectin receptors; GITR, glucocorticoid-induced TNFR family related gene; ITIM, immunoreceptor tyrosine-based 
inhibition motif; RA, retinoic acid.
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